Objective: The primary objective of this trial was to evaluate the feasibility, safety, and efficacy of a predictive hyperglycemia and hypoglycemia minimization (PHHM) system vs predictive low glucose suspension (PLGS) alone in optimizing overnight glucose control in children 6 to 14 years old.
| INTRODUCTION
The overnight period is a particularly perilous time for patients with type 1 diabetes (T1D) especially with regard to the dangers from prolonged nocturnal hypoglycemia. 1, 2 It has been well documented that patients with T1D have decreased counter-regulatory hormone responses during sleep 3 as well as increased arousal thresholds 4 Abbreviations: AID, automated insulin delivery; CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin infusion; HbA1c, glycated hemoglobin; HCL, hybrid closed loop; IOB, insulin-on-board; IQR, interquartile range; LGS, low glucose suspend; PHHM, predictive hyperglycemia and hypoglycemia minimization; PLGS, predictive low glucose suspend; SAP, sensor augmented pump; T1D, type 1 diabetes limiting the ability of many patients to detect and respond to nocturnal hypoglycemia. Prolonged nocturnal hypoglycemia can lead to severe consequences such as hypoglycemic seizures 5 and even death from the so-called dead-in-bed syndrome. 6 In pediatric patients, in particular, parental fear of hypoglycemia has been linked to increased parental stress which in turn has been linked to worse glycemic control. 7 Overnight continuous glucose monitoring (CGM) used alone or in a sensor augmented pump (SAP) fashion has proven inadequate to prevent overnight hypoglycemia as patients tend to become desensitized to overnight alarms. 8 While monitoring alone may not be sufficient to reduce or alleviate the risk and burden of nocturnal hypoglycemia, existing and emerging automated insulin delivery (AID) systems show significant promise to accomplish this aim. AID systems combine a CGM sensor, continuous subcutaneous insulin infusion (CSII) pump, and control algorithm which modulates delivery of insulin and/or other hormones, such as glucagon or amylin. [9] [10] [11] AID may be limited to suspension of insulin delivery or may involve suspending, reducing, or increasing insulin delivery based on CGM values. Much initial work has focused on the role of AID in the overnight period to mitigate hypoglycemia with studies showing significant reduction in hypoglycemia across multiple system designs. [12] [13] [14] [15] As AID systems have now progressed to longitudinal outpatient studies, the major consistent theme has been the success of overnight control, particularly the reduction in nocturnal hypoglycemia. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Many trials in the pediatric age group have even targeted diabetes camp settings and found significant hypoglycemia reduction with AID use even in this remarkably challenging setting in children. 15, 20, 21, [26] [27] [28] Table S1 (Supporting information).
| System
Closed-loop control was implemented using a control algorithm on a 
| Synopsis of study protocol
A run-in phase preceded the randomized trial. During the initial part of the run-in phase, the sensor was initiated and used for 14 to 21 days to verify that the participant could successfully use the pump and sensor. Successful participants then used the complete system with PHHM mode activated at home for 5 nights to verify the ability to use it successfully. Six participants withdrew without proceeding to the randomized trial due to logistical issues or dissatisfaction with system components during the run-in phase and one due to HbA1c screening failure ( Figure S1 ).
During the randomized trial, the system was used until 42 nights with at least 4 hours of sensor glucose data per night were completed.
Each night, following initiation procedures which included verification that the meter-measured blood glucose was between 90 and 270 mg/ dL, the system randomly activated either PHHM or PLGS according to a predefined schedule with the aim of completing 21 nights with PHHM and 21 nights with PLGS. Participants were blinded to the assignment.
Participants were advised to use the system on consecutive nights if possible but to avoid system use during periods of illness. The maximum number of days allowed by the study to complete the 42 nights was 90 days. Upon waking, the system was stopped, a meter blood glucose was measured and overnight carbohydrate intake was recorded. Participants were instructed to perform a blood ketone test if blood glucose was ≥300 mg/dL for over 1 hour or ≥400 mg/dL at any point during system use. Since participants and their families typically did not follow the ketone testing instructions based on retrospective assessment of blood glucose and ketone meter data, the ketone data were considered incomplete and were not included in analyses. During the day, participants used the Veo pump and Enlite glucose sensor (Medtronic Diabetes, Northridge, CA) in sensor-augmented pump mode only. The thresholdbased LGS feature of the Veo pump was disabled during the study.
During the randomized trial, study visits occurred after 21 days and after completion of the study. HbA1c was measured using a ), and any study-or device-related event.
| Statistical methods
The statistical methods were similar to the ones previously described 31 and are briefly summarized here.
The primary outcome was percentage of time in range 70 to 180 mg/dL pooled across nights. Analyses followed the intention-totreat principle, with each night analyzed by the treatment arm assigned by randomization, and with all participants and all randomized nights included in the primary analysis. All other efficacy metrics were considered secondary exploratory analyses and no adjustment was made for multiple comparisons.
Repeated-measures regression models with an unstructured covariance structure were used to test the differences between the 2 treatment arms, while adjusting for the averaged bedtime blood glucose value across nights for the primary and all other participantlevel outcomes. Logarithmic or square-root transformations were used for secondary outcome variables with a skewed distribution.
Additional analyses were performed for night-level secondary outcomes (eg, proportion of nights with at least 1 sensor glucose concentration <70 mg/dL). These analyses were restricted to nights with at least 4 hours of available sensor data. Generalized linear mixed models with a logistic link function for binary outcomes or identity link function for continuous outcomes were used to test the differences between the 2 treatment arms using random participant effects and a within-participant autocorrelation structure to account for multiple nights from the same participant, while adjusting for the bedtime blood glucose. All P-values are 2-tailed and analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, North Carolina).
Analyses for percentage time glucose below 54 mg/dL, area over curve 54 mg/dL, and proportion of nights with nadir below 54 mg/dL events were added posthoc. The methods for the first two paralleled the pooled analyses, while the last paralleled the night-level analyses.
| RESULTS
The trial included 28 participants, 6 to 14 years of age, 46% male, 79% Caucasian, with median T1D duration of 4 years, median HbA1c level of 7.6% (60 mmol/mol) at study enrollment, and a median daily insulin dose of 0.83 U/kg/day ( Figure 1 ). Figure S3 shows that all participants, except one, had a higher percentage time 70 to 180 mg/dL on the PHMM nights compared with the PLGS nights. Mean AE SD overnight mean sensor glucose was 160 AE 15 mg/dL during PLGS nights vs 147 AE 13 mg/dL during PHHM nights (P<.001, Figure 2 ). Median overnight sensor coefficient of variation (CV) was 35% (IQR 30%, 38%) during PLGS nights vs 32% (IQR 28%, 36%) during PHHM nights (P=.01, Figure 2 ). As shown in Figures 1 and 2 , the PHHM system required approximately 3 hours from the time of activation before improvements in glycemic metrics compared with PLGS started to appear, and the curves were still diverging at 8 hours.
Median time below 70 mg/dL was 1.8% (IQR 0.9%, 2.6%) during PLGS nights and 1.8% (IQR 1.0%, 2.9%) during PHHM nights (P=.76).
Other sensor-measured hypoglycemic outcomes also were similar between PLGS and PHHM nights (Tables 1 and S5 Figure S4 ).
Sensor data were available to the controller for an average across participants of 90% of the time the system was running on randomized nights (Table S6) . During PHHM nights, the system delivered 92% of the automatic boluses requested by the controller within 5 minutes.
Among 7071 sensor-meter glucose pairs obtained during day and night CGM use, the overall median difference for the Enlite glucose sensor was −6 mg/dL (IQR: −28, +12), median ARD was 13% (IQR: 6%, 24%), mean ARD was 18%, and 59% of pairs met the ISO criteria. T1D. 41 The study found significant improvement in self-reported sleep quality for the adult participants on HCL compared to LGS but no significant improvement for the adolescents. This project however did not study the parents of children with T1D and did not compare HCL or LGS to conventional SAP therapy alone. Earlier work by Barnard et al comparing overnight HCL therapy with SAP therapy in adolescents 12 to 18 years old found that the psychological benefits of closed-loop systems were significant and improved sleep in a majority of adolescents and their parents. 42 The results from this project compare very favorably with other AID trials investigating overnight control in pediatric populations. showed for adolescents 14 to 21 years old an overnight % <70 mg/ dL of 3.2% with average CGM value of 145.9 mg/dL and 7 AM CGM value of about 142 mg/dL. 17, 22 This average CGM value is very similar to the 147 mg/dL observed during PHHM nights of the current study, though the 670G system reduces hyperglycemia by increasing basal insulin rather than delivering small correction boluses. The results from our pediatric cohort also compare favorably with our recently published adult cohort which reported that with PHHM the % <70 mg/dL overnight was 1.1%, time in target range 70 to 180 mg/dL was 78%, mean CGM glucose was 143 mg/dL, and mean AM blood glucose was 142 mg/dL. 31 The Medtronic 640G is a PLGS system introduced in various parts of the world, but never released in the United States. The 640G system suspends insulin infusion when 2 criteria are met: the sensor glucose is at or within 70 mg/dL above the set low limit and is predicted to be 20 mg/dL above the set low limit in 30 minutes. 46 The 640G algorithm thus uses a similar set of threshold and prediction 
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A significant strength for this study is its scientific design in which the system mode (PLGS vs PHHM) was randomly selected each night and the study participant was blinded to this assignment. The inclusion/ exclusion criteria were relatively broad allowing patients with an HbA1c of <10.0% to participate in the trial, helping to improve generalizability.
A limitation of this study is that the AID system did not have an adaptive component in that the algorithm did not "learn" day-to-day based on previous data. Another potential limitation is that participants were remotely monitored overnight by study staff and parents were contacted for prolonged hypoglycemia. However, this safety constraint was present on both PLGS and PHHM nights with a similar incidence rate (Table S6) . Prior to randomized system use by any participant, there was 1 bolus command error resulting in over-delivery and subsequent hypoglycemia, for which remote monitoring prevented a potential severe adverse event. Although this prototype system did rely on the pump manufacturer's unmodified wireless security implementation, the pump itself was not designed or approved for frequent insulin dosing via wireless control. After review of this event with the data safety committee, Food and Drug Administration (FDA), and IRB, a maximum bolus size constraint of 1.0 U was introduced both in software and hardware to mitigate such events for the remainder of the study.
Although any AID system with wireless transmission of bolus commands is in principle vulnerable to signal corruption, commercialized systems will generally have very robust error-detecting code to identify and reject corrupted commands.
The per-night randomized nature of this trial prevented assessment of the respective impacts of the PLGS and PHHM components on HbA1c, and use of these components in previous studies was not associated with an increase in HbA1c. [29] [30] [31] The overall goals of the project were to limit hypoglycemia with hyperglycemia minimization added to help minimize secondary hyperglycemia associated with insulin suspension. Based on these goals, reduction of hypoglycemia without increasing HbA1c may be viewed as a success of the project aims.
In conclusion, the PHHM system performed very well in this pediatric population, achieving 76% overnight time in the range of 70 to 180 mg/dL with no increase in hypoglycemia compared with PLGS alone. This was achieved in a customizable system used at home, overnight with minimal system maintenance in a pediatric population allowing for improved glycemic control during what is for many families the most stressful time for T1D management.
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